J-Pharma Co., Ltd.

J-Pharma and Uniphar Advance First-in-Class LAT1 Inhibitor Nanvuranlat into Global Phase 3 Trial for Biliary Tract Cancer

- J-Pharma and Uniphar announced FDA alignment and advancement of nanvuranlat (JPH203), a first-in-class LAT1 inhibitor, into a global Phase 3 study for second-line biliary tract cancer. - Initial patients have been enrolled and randomized in the global study, which builds on Phase 1 and Phase 2 data from Japan showing encouraging efficacy and safety signals. - The strategic partnership with Uniphar Development enabled a targeted regulatory strategy that bypassed the need for an additional Phase 2 study before Phase 3. - Nanvuranlat targets a metabolic dependency of cancer cells via LAT1 inhibition, potentially offering a new option for patients without actionable genetic mutations.